Compare Merck & Co., Inc. (MRK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Merck & Co., Inc. trades at $148.65 (market cap $350.29B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Merck & Co., Inc. is far larger — about 46.6× Spyre Therapeutics Inc. Common Stock's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MRK | SYRE | |
|---|---|---|
Market Cap | $350.29B | $7.52B |
Volume | 8,158,912 | 1,441,031 |
Sector | Health | Health |
52-Week High | $156.43 | $108.92 |
52-Week Low | $82.49 | $22.18 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $6.52B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $147.37, up 1.32% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and a $6.7 billion acquisition of Terns Pharmaceuticals highlight growth momentum. Revenue reached $65.01 billion in 2025, with net income at $18.25 billion, though the P/E ratio of 113.58 reflects high valuation expectations.
Outlook is positive with a consensus price target of $158.50, but risks include patent expirations, regulatory scrutiny, and integration challenges from acquisitions. The stock's premium valuation requires sustained earnings growth to justify further upside, with investor sentiment bolstered by analyst support and strategic pipeline expansion.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
